We also observed that the distribution of TP53 mutations differs in various tumor types, ranging from 7.3 to 94.9% in the case of multiple myeloma (MM) and ovarian serous cystadenocarcinoma (OVCA) respectively (Supplementary file 1). The gene discussed is TP53; the disease is plasma cell myeloma.